Literature DB >> 8747520

Study on pharmacokinetics of radioactive labelled defibrotide after oral or intravenous administration in rats.

J Fisher1, T K Holland, R Pescador, R Porta, L Ferro.   

Abstract

Defibrotide (D) was labelled with 125I or with 32P. The radiolabelled compounds ([125I]-Defibrotide ([125I]-D), [32P]-Defibrotide ([32P]-D) retained the same profibrinolytic activity, in vitro, as the parent drug, suggesting that the labelling procedures had not modified the pharmacological properties of D and hence that its chemical structure was not affected significantly. After single intravenous or oral administration of [125I]-D or [32P]-D the pharmacokinetic parameters for the two labels were generally in good agreement (75%). t 1/2 alpha was in the range of minutes while t 1/2 beta was in the range of hours. Bioavailability, following single oral administration of [125I]-D or [32P]-D, was in the range of 58-70%. These data suggest that D, in spite of its macromolecular nature, is absorbed, after oral administration, fairly well.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8747520     DOI: 10.1016/0049-3848(95)00213-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance.

Authors:  Marta Palomo; Enrique Mir; Montse Rovira; Ginés Escolar; Enric Carreras; Maribel Diaz-Ricart
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

Review 2.  Defibrotide in the treatment of hepatic veno-occlusive disease.

Authors:  Alessandro Fulgenzi; Maria Elena Ferrero
Journal:  Hepat Med       Date:  2016-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.